Skip to main content
. 2017 Sep 28;4(2):e172908. doi: 10.1001/jamaoncol.2017.2908

Figure 1. Enrollment in the Study.

Figure 1.

Patients with histologically confirmed stage IB to IIIA cutaneous melanoma and no evidence of metastasis were eligible to participate in the study. They were divided into a propranolol cohort and a nonpropranolol cohort.